TY  - JOUR
AU  - Antonia, Scott J
AU  - Villegas, Augusto
AU  - Daniel, Davey
AU  - Vicente, David
AU  - Murakami, Shuji
AU  - Hui, Rina
AU  - Kurata, Takayasu
AU  - Chiappori, Alberto
AU  - Lee, Ki H
AU  - de Wit, Maike
AU  - Cho, Byoung C
AU  - Bourhaba, Maryam
AU  - Quantin, Xavier
AU  - Tokito, Takaaki
AU  - Mekhail, Tarek
AU  - Planchard, David
AU  - Kim, Young-Chul
AU  - Karapetis, Christos S
AU  - Hiret, Sandrine
AU  - Ostoros, Gyula
AU  - Kubota, Kaoru
AU  - Gray, Jhanelle E
AU  - Paz-Ares, Luis
AU  - de Castro Carpeño, Javier
AU  - Faivre-Finn, Corinne
AU  - Reck, Martin
AU  - Vansteenkiste, Johan
AU  - Spigel, David R
AU  - Wadsworth, Catherine
AU  - Melillo, Giovanni
AU  - Taboada, Maria
AU  - Dennis, Phillip A
AU  - Özgüroğlu, Mustafa
AU  - PACIFIC Investigators
PY  - 2018
DO  - 10.1056/NEJMoa1809697
UR  - http://hdl.handle.net/10668/13018
T2  - The New England journal of medicine
AB  - An earlier analysis in this phase 3 trial showed that durvalumab significantly prolonged progression-free survival, as compared with placebo, among patients with stage III, unresectable non-small-cell lung cancer (NSCLC) who did not have disease...
LA  - en
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal
KW  - Antineoplastic Agents, Immunological
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Chemoradiotherapy
KW  - Female
KW  - Humans
KW  - Infusions, Intravenous
KW  - Intention to Treat Analysis
KW  - Kaplan-Meier Estimate
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Survival Rate
TI  - Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
TY  - research article
VL  - 379
ER  -